Home Tags MilliporeSigma

Tag: MilliporeSigma

A New Horizon in ADC Technology: A Panel Discussion

Targeted therapies such as antibody-drug conjugates (ADC) have opened new ways in targeting diseases like cancer and hematological malignancies. High-potent active pharmaceutical ingredients, also...

World ACD London: How MilliporeSigma helps Accelerates and Enhances ADC Therapies

With the 12th Annual World ADC London, Europe’s longest standing antibody-drug conjugate event behind us, let's look back at some of the highlights. With the...

Comprehensive Service Accelerates Development of ADCs and Reduces Time to Clinic

A new service called ADC Express™services, launched by MilliporeSigma, allows for the rapid production of Antibody-drug Conjugates or ADCs. The service is expected to...
Discover Opportunities In Your Data

MilliporeSigma Acquires Data Management and Analysis Platform for Biopharma Real-Time Process...

Web-based platform provides easy on-demand access, across functions and with suppliers, to data for aggregation, analysis, visualization and management Advances company’s BioContinuum™ Platform...
Pellicon® Capsules

Recorded Webinar – Development of a new Antibody-drug Conjugate Diafiltration Process...

Recorded: June 14, 2017 Speaker: Eric Lacoste, Head of ADC Process Development Team at Sanofi Title: Development of a new Antibody-drug Conjugate Diafiltration Process and Use...

Three U.S. Companies Awarded MilliporeSigma’s Advance Biotech Grant

MilliporeSigma Awards Grants to Biotechs Focused on Traumatic Brain Injury, Vaccine Development and Chronic Pain. MilliporeSigma today announced the winners of its Advance Biotech Grant program...
Featured Image: Pellicon® Capsule. Courtesy: © 2019 MilliporeSigma. Used with permission.

Download the Application Note on the Pellicon® Capsule

Tangential flow filtration (TFF) is essential in the manufacturing of antibody drug conjugates (ADCs). Ultrafiltration (UF) is used to concentrate the protein product and...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

MilliporeSigma and Angiex Collaborate to Speed-up Clinical Readiness for the Development...

MilliporeSigma, the US-based life science business of Merck KGaA, Darmstadt, Germany, has agreed to support Cambridge, Massachusetts-based Angiex ability to speed-up the development of...

Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically conjugated to a cytotoxic drug...

X